Rocket Pharmaceuticals Inc (RCKT)

Apr 10, 2025, 11:16 AM EDT - 13 days ago

Rocket Pharma Out Of Orbit, But Ready For Relaunch

Apr 3, 2025, 7:00 AM EDT - 20 days ago

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Feb 27, 2025, 4:01 PM EST - 7 weeks ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Feb 12, 2025, 3:40 PM EST - 2 months ago

Rocket Pharma Is A Buy At These Prices With Promising Data

Jan 6, 2025, 7:19 AM EST - 3 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO OTLK

Jan 2, 2025, 4:00 PM EST - 3 months ago

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 3:00 PM EST - 4 months ago

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Dec 11, 2024, 7:00 AM EST - 4 months ago

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Dec 10, 2024, 4:01 PM EST - 4 months ago

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Nov 26, 2024, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 2:47 PM EST - 5 months ago

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Nov 18, 2024, 11:00 AM EST - 5 months ago

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Nov 12, 2024, 4:01 PM EST - 5 months ago

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Nov 8, 2024, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 5 months ago

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Sep 19, 2024, 3:18 PM EDT - 7 months ago

Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves

Sep 17, 2024, 7:00 AM EDT - 7 months ago

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Sep 10, 2024, 7:00 AM EDT - 8 months ago

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Aug 27, 2024, 7:00 AM EDT - 8 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 5, 2024, 4:01 PM EDT - 9 months ago

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Jul 29, 2024, 3:32 PM EDT - 9 months ago

3 Biotech Names With Potential Catalysts By Year End

CADL VRDN

Jun 28, 2024, 1:26 PM EDT - 10 months ago

FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

Jun 28, 2024, 7:27 AM EDT - 10 months ago

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

May 29, 2024, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

May 10, 2024, 6:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 6, 2024, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Apr 5, 2024, 11:50 AM EDT - 1 year ago

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 2, 2024, 2:34 PM EDT - 1 year ago

Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch

Apr 2, 2024, 6:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Mar 1, 2024, 6:03 PM EST - 1 year ago

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Feb 26, 2024, 4:01 PM EST - 1 year ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Feb 13, 2024, 7:00 AM EST - 1 year ago

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Jan 2, 2024, 4:01 PM EST - 1 year ago

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 1:24 PM EST - 1 year ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH IMVT PRVA

Dec 12, 2023, 7:00 AM EST - 1 year ago

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

Nov 6, 2023, 4:04 PM EST - 1 year ago

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Oct 19, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Oct 2, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Sep 26, 2023, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference

Sep 21, 2023, 7:30 AM EDT - 1 year ago

Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook

Sep 14, 2023, 9:40 AM EDT - 1 year ago

Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?

Sep 13, 2023, 10:54 AM EDT - 1 year ago

Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential 'Value Driver.

Sep 13, 2023, 12:01 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Sep 12, 2023, 4:01 PM EDT - 1 year ago

Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Aug 3, 2023, 12:42 AM EDT - 1 year ago

Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts

Jun 8, 2023, 8:25 AM EDT - 2 years ago

Rocket Pharmaceuticals shares rise on FDA fast-track designation for heart disease treatment

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

May 31, 2023, 7:00 AM EDT - 2 years ago

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease